Skip to content

EBITDA at other companies

Eli Lilly logo
Eli LillyLLY
Medtronic logo
MedtronicMDT
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Abbott logo
AbbottABT
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Calculated from Insulet’s reported figures.

$122.1Mebit+
$26.2MDepreciation Depletion & Amortization
=$148.3M

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's EBITDA?
Insulet (PODD) reported EBITDA of $148.3M in Q1 2026.
How has Insulet's EBITDA changed year-over-year?
Insulet's EBITDA increased by 34.2% year-over-year, from $110.5M to $148.3M.
What is the long-term trend for Insulet's EBITDA?
Over 4 years (2021 to 2025), Insulet's EBITDA has grown at a 32.4% compound annual growth rate (CAGR), from $183.4M to $564.3M.
What does EBITDA mean?
Operating cash profit before interest, taxes, and non-cash charges.
How do you interpret EBITDA?
Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
How does EBITDA compare across companies?
Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.